Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have given a strong buy recommendation to the company.
RBGLY has been the topic of several recent analyst reports. Citigroup upgraded shares of Reckitt Benckiser Group to a "strong-buy" rating in a research note on Tuesday, October 1st. Barclays upgraded Reckitt Benckiser Group to a "strong-buy" rating in a report on Friday, October 4th. JPMorgan Chase & Co. cut Reckitt Benckiser Group from an "overweight" rating to a "neutral" rating in a report on Thursday, August 29th. UBS Group raised shares of Reckitt Benckiser Group to a "strong-buy" rating in a report on Wednesday, September 18th. Finally, Sanford C. Bernstein cut shares of Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 4th.
View Our Latest Stock Analysis on Reckitt Benckiser Group
Reckitt Benckiser Group Stock Down 1.4 %
RBGLY stock traded down $0.17 during trading on Tuesday, reaching $12.17. 376,029 shares of the stock were exchanged, compared to its average volume of 902,518. Reckitt Benckiser Group has a twelve month low of $10.24 and a twelve month high of $15.03. The stock has a 50 day simple moving average of $12.29 and a 200-day simple moving average of $11.61. The company has a quick ratio of 0.47, a current ratio of 0.69 and a debt-to-equity ratio of 0.97.
Reckitt Benckiser Group Company Profile
(
Get Free ReportReckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
